Institute of Resource Development and Analysis, Kumamoto University, Kumamoto, Japan.
Department of Gastroenterological Surgery, Kumamoto University, Kumamoto, Japan.
Oncogene. 2016 May 5;35(18):2407-12. doi: 10.1038/onc.2015.294. Epub 2015 Aug 10.
Intraductal papillary mucinous neoplasm (IPMN), the most common pancreatic cystic neoplasm, is known to progress to invasive ductal adenocarcinoma. IPMNs commonly harbor activating somatic mutations in GNAS and KRAS, primarily GNAS(R201H) and KRAS(G12D). GNAS encodes the stimulatory G-protein α subunit (Gsα) that mediates a stimulatory signal to adenylyl cyclase to produce cyclic adenosine monophosphate (cAMP), subsequently activating cAMP-dependent protein kinase A. The GNAS(R201H) mutation results in constitutive activation of Gsα. To study the potential role of GNAS in pancreatic tumorigenesis in vivo, we generated lines of transgenic mice in which the transgene consisted of Lox-STOP-Lox (LSL)-GNAS(R201H) under the control of the CAG promoter (Tg(CAG-LSL-GNAS)). These mice were crossed with pancreatic transcription factor 1a (Ptf1a)-Cre mice (Ptf1a(Cre/+)), generating Tg(CAG-LSL-GNAS);Ptf1a(Cre/+) mice. This mouse line showed elevated cAMP levels, small dilated tubular complex formation, loss of acinar cells and fibrosis in the pancreas; however, no macroscopic tumorigenesis was apparent by 2 months of age. We then crossed Tg(CAG-LSL-GNAS);Ptf1a(Cre/+) mice with LSL-Kras(G12D) mice, generating Tg(CAG-LSL-GNAS);LSL-Kras(G12D);Ptf1a(Cre/+) mice. We used these mice to investigate a possible cooperative effect of GNAS(R201H) and Kras(G12D) in pancreatic tumorigenesis. Within 5 weeks, Tg(CAG-LSL-GNAS);LSL-Kras(G12D);Ptf1a(Cre/+) mice developed a cystic tumor consisting of marked dilated ducts lined with papillary dysplastic epithelia in the pancreas, which closely mimicked the human IPMN. Our data strongly suggest that activating mutations in GNAS and Kras cooperatively promote murine pancreatic tumorigenesis, which recapitulates IPMN. Our mouse model may serve as a unique in vivo platform to find biomarkers and effective drugs for diseases associated with GNAS mutations.
导管内乳头状黏液性肿瘤(IPMN)是最常见的胰腺囊性肿瘤,已知其会进展为浸润性导管腺癌。IPMN 通常在 GNAS 和 KRAS 中存在激活的体细胞突变,主要为 GNAS(R201H)和 KRAS(G12D)。GNAS 编码刺激 G 蛋白 α 亚单位(Gsα),它介导刺激信号至腺苷酸环化酶以产生环磷酸腺苷(cAMP),随后激活 cAMP 依赖性蛋白激酶 A。GNAS(R201H)突变导致 Gsα 的组成性激活。为了研究 GNAS 在体内胰腺肿瘤发生中的潜在作用,我们生成了转基因小鼠系,其中转基因由 CAG 启动子(Tg(CAG-LSL-GNAS))控制下的 Lox-STOP-Lox (LSL)-GNAS(R201H)组成(Tg(CAG-LSL-GNAS))。这些小鼠与胰腺转录因子 1a (Ptf1a)-Cre 小鼠(Ptf1a(Cre/+))杂交,生成 Tg(CAG-LSL-GNAS);Ptf1a(Cre/+) 小鼠。该小鼠系显示 cAMP 水平升高、小的扩张管状复合物形成、腺泡细胞丧失和胰腺纤维化;然而,在 2 个月大时,没有明显的肿瘤发生。然后,我们将 Tg(CAG-LSL-GNAS);Ptf1a(Cre/+) 小鼠与 LSL-Kras(G12D) 小鼠杂交,生成 Tg(CAG-LSL-GNAS);LSL-Kras(G12D);Ptf1a(Cre/+) 小鼠。我们使用这些小鼠来研究 GNAS(R201H)和 Kras(G12D)在胰腺肿瘤发生中的可能协同作用。在 5 周内,Tg(CAG-LSL-GNAS);LSL-Kras(G12D);Ptf1a(Cre/+) 小鼠在胰腺中发展出一种囊性肿瘤,由明显扩张的导管组成,导管内衬有乳头状发育不良的上皮,这与人类 IPMN 非常相似。我们的数据强烈表明,GNAS 和 Kras 中的激活突变协同促进了小鼠胰腺肿瘤的发生,这再现了 IPMN。我们的小鼠模型可能成为寻找与 GNAS 突变相关疾病的生物标志物和有效药物的独特体内平台。